#mounjaro

6 articles tagged #mounjaro.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

#2026 4 #503a 1 #503b 2 #alcohol 1 #alternatives 1 #ban 1 #before-and-after 1 #beginners 2 #berberine 1 #brand-name 3 #bridge-program 1 #cagrilintide 1 #cagrisema 1 #clinical-research 1 #clinical-trials 1 #comparison 2 #compounded 8 #compounded-glp1 1 #compounded-semaglutide 1 #compounded-tirzepatide 1 #compounding-ban 1 #copay 1 #cost 13 #coupon 1 #coverage 1 #diabetes 1 #diet 1 #dosage 1 #eli-lilly 3 #enforcement 1 #enrollment 1 #fact-check 2 #fda 4 #fda-approval 1 #flat-rate 1 #foundayo 7 #framework 1 #glp-1-patches 1 #glucose-monitors 1 #guide 1 #hhs 1 #hims 1 #how-to-get 1 #injectable 7 #injection 1 #insulin-resistance 1 #insurance 11 #ivy-rx 1 #ivyrx 1 #legality 1 #liraglutide 1 #medicaid 1 #medicare 5 #mounjaro 6 #natures-ozempic 1 #news 2 #novo-nordisk 2 #online-prescription 1 #oral-glp1 6 #oral-semaglutide 1 #orforglipron 4 #ozempic 9 #pcos 1 #personalized-treatment 1 #pill 1 #pipeline 1 #policy 1 #precision-medicine 1 #prior-authorization 2 #regulation 2 #results 1 #rfk 1 #ro 2 #safety 5 #savings-card 1 #schedule 1 #semaglutide 24 #serena-williams 1 #shortage 1 #side-effects 10 #storage 1 #supplements 2 #surmount 2 #surmount-5 1 #telehealth 1 #telehealth-enforcement 1 #telehealth-review 1 #timeline 1 #tirzepatide 22 #travel 1 #tsa 1 #type-2-diabetes 1 #wada 1 #warning-letters 1 #wegovy 17 #wegovy-hd 1 #wegovy-pill 3 #weight-loss 26 #weight-loss-plateau 1 #without-insurance 1 #zepbound 18

Editorial still-life illustrating a head-to-head semaglutide and tirzepatide comparison

Analysis ComparisonsJuly 15, 2026• 14 min read

Semaglutide vs Tirzepatide (2026): 13.7% vs 20.2% Weight Loss, Head-to-Head SURMOUNT-5

Updated July 2026: Tirzepatide produces 20.2% weight loss vs semaglutide's 13.7% in the SURMOUNT-5 head-to-head trial (NEJM 2024): a 47% greater relative reduction confirmed by 2026 systematic meta-analyses. Tirzepatide activates GLP-1 + GIP dual receptors; semaglutide activates GLP-1 only. Full cost and side-effect comparison.

Editorial still-life illustrating two parallel paths, a calm side-by-side comparison

Analysis ComparisonsJune 24, 2026• 11 min read

Mounjaro vs Ozempic (2026): The Honest Head-to-Head Your Doctor Won't Have Time For

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both FDA-approved only for type 2 diabetes, neither is approved for weight loss (that's their sister brands, Zepbound and Wegovy). In the first head-to-head trial, SURMOUNT-5, tirzepatide beat semaglutide for weight loss (−20.2% vs −13.7% over 72 weeks), and in SURPASS-2 tirzepatide cut A1C more. But Ozempic's semaglutide has the SELECT cardiovascular outcome data Mounjaro doesn't. Here's the data-driven breakdown, plus the cheaper cash-pay paths if your insurance says no.

Editorial lifestyle photograph accompanying a tirzepatide dosage chart and weight loss schedule guide

Guide GuidesMay 7, 2026• 9 min read

Tirzepatide Dosage Chart for Weight Loss 2026: Complete Schedule (Zepbound, Mounjaro & Compounded)

Verified May 2026: Tirzepatide starts at 2.5 mg once weekly (non-therapeutic starter dose), escalates by 2.5 mg every 4 weeks to a maximum of 15 mg once weekly. Full escalation takes 20 weeks. At 72 weeks, the 15 mg dose produced 20.9% body weight loss in SURMOUNT-1, equivalent to roughly 47 lbs for a 225-lb person. The 5 mg and 10 mg doses are also valid long-term maintenance doses (15% and 19.5% weight loss respectively). Same dosing schedule applies to Zepbound, Mounjaro, and compounded tirzepatide.

Editorial photograph illustrating a comparison of Zepbound and Mounjaro tirzepatide medications

Analysis ComparisonsApril 22, 2026• 12 min read

Zepbound vs Mounjaro (April 2026): Same Drug, Different Labels, Which Is Right for You?

Verified July 2026: Zepbound and Mounjaro are the exact same drug (tirzepatide) at the same doses. Mounjaro was FDA-approved May 2022 for Type 2 diabetes. Zepbound was FDA-approved November 2023 for chronic weight management and December 2024 for obstructive sleep apnea. List price is ~$1,087/mo for both; with commercial insurance + savings cards both drop to $25/mo (max $1,950/yr). The real differences: which one your insurance covers, what the FDA label allows, and Zepbound's LillyDirect self-pay vials at $299-$449/mo, a program Mounjaro does not offer.

Editorial still-life illustrating tirzepatide cost options for 2026

Analysis Cost & InsuranceApril 11, 2026• 14 min read

Tirzepatide Cost 2026: $149 to $1,086/Month, Every Option Ranked (Verified July 2026)

Verified August 2026: Tirzepatide prices include $149/mo via Gala on a yearly microdose plan ($169/mo for 3 months), $299/mo via LillyDirect (brand Zepbound 2.5mg vial), $399 for the 5mg vial, $449 for 7.5mg and higher doses when refill conditions are met, $25/mo with an eligible Zepbound savings card, or $1,086/mo retail list price. Full price breakdown with 54 tracked providers.

Editorial still-life illustrating Zepbound and Mounjaro savings card programs

Guide Cost & InsuranceApril 11, 2026• 11 min read

Zepbound & Mounjaro Savings Card (2026): $25/mo Copay + $1,300 Annual Savings

Verified July 2026: Zepbound savings card cuts copay to $25/fill ($1,300 max annual savings) with commercial insurance. Mounjaro savings card offers $25 copay for T2D. Both expire Dec 31, 2026. Activate in 2 minutes at zepbound.lilly.com/savings. Full eligibility + backup options.